OncoMatch/Clinical Trials/NCT06090539
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Is NCT06090539 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments for relapsed/refractory non-hodgkin lymphoma.
Treatment: BMS-986458 · Rituximab · Glofitamab/Obinutuzumab · Mosunetuzumab · Epcoritamab · Golcadomide — The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: CAR-T cell therapy
Participants must not have prior CAR-T
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona - Phoenix · Phoenix, Arizona
- City of Hope Comprehensive Cancer Center · Duarte, California
- Local Institution - 0068 · Jacksonville, Florida
- Moffitt Cancer Center · Tampa, Florida
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06090539 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages